Real experience of prophylaxis with emicizumab in patients with congenital haemophilia A with and without FVIII inhibitors in the HCUVA

被引：0

作者：

Heredia Cano, Angela ^{[1
]}

Garcia Candel, Faustino ^{[1
]}

Sanchez Villalobos, Maria ^{[1
]}

Poveda Garcia, Andrea ^{[1
]}

Torchia Esteban, Marcos ^{[1
]}

Ruiz Ruiz, Estela ^{[1
]}

Sanchez Salas, Jose Antonio ^{[1
]}

Navarro Almenzar, Begona ^{[1
]}

Caracena Lopez, Sara ^{[2
]}

Perez Laencina, Marta ^{[1
]}

Blazquez Soto, Juan Antonio ^{[1
]}

机构：

[1] Hosp Clin Univ Virgen de la Arrixaca, Murcia, Spain

[2] Hosp Gen Univ Morales Meseguer, Murcia, Spain

来源：

HAEMOPHILIA | 2024年 / 30卷

关键词：

congenital haemophilia A; emicizumab; real experience;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PP-022 (1

引用

页码：31 / 32

页数：2

共 50 条

[31] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
Mahlangu, J.
Oldenburg, J.
Paz-Priel, I.
Negrier, C.
Niggli, M.
Mancuso, M. E.
Schmitt, C.
Jimenez-Yuste, V.
Kempton, C.
Dhalluin, C.
Callaghan, M. U.
Bujan, W.
Shima, M.
Adamkewicz, J. I.
Asikanius, E.
Levy, G. G.
Kruse-Jarres, R.
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 811 - 822
[32] EMICIZUMAB PROPHYLAXIS IN SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: OUTCOME AND INDICATIONS. FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION
Hay, C. R. M.
Wall, C.
Xiang, H.
Palmer, B.
Chowdary, P.
Collins, P.
Fletcher, S.
Hall, G. W.
Mathias, M.
Percy, C.
Sartain, P.
Susan, S.
Stephensen, D.
Talks, K.
HAEMOPHILIA, 2022, 28 : 50 - 51
[33] EMICIZUMAB PROPHYLAXIS IN SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: OUTCOME AND INDICATIONS. FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION
Hay, C.
Wall, C.
Xiang, H.
Palmer, B.
Chowdary, P.
Collins, P.
Fletcher, S.
Mathias, M.
Percy, C.
Sartain, P.
Shapiro, S.
Stephensen, D.
Talks, K.
HAEMOPHILIA, 2023, 29 : 78 - 79
[34] Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors
Pinto, Patricia
Shetty, Shrimati
Lacroix-Desmazes, Sebastien
Bayry, Jagadeesh
Kaveri, Srini
Ghosh, Kanjaksha
IMMUNOLOGY LETTERS, 2016, 169 : 93 - 97
[35] Prophylaxis with emicizumab in 50 children and adolescents with severe haemophilia A without inhibitor in Uruguay: National experience
Lemos, Felipe
Petraccia, Carlos
Laura Fraga, Maria
Gomez, Rosario
Lutz, Stefani
Laura Casuriaga, Ana
Inguanzo, Marianella
Gonzalez, Jimena
Echeverria, Silvina
Gomez, Florencia
Arocena, Maria
Gonzalez, Yenirellys
Giachetto, Gustavo
Boggia, Beatriz
HAEMOPHILIA, 2024, 30 : 96 - 97
[36] Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A
Lindgren, A
Wadenvik, H
Tengborn, L
HAEMOPHILIA, 2002, 8 (05) : 644 - 648
[37] EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A PATIENTS WITH INHIBITORS: A COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS
Cortesi, P. A.
Castaman, G.
Trifiro, G.
Ferrario, M.
Improta, G.
Mazzaglia, G.
Molinari, A. C.
Mantovani, L. G.
VALUE IN HEALTH, 2019, 22 : S845 - S845
[38] Tertiary prophylaxis in patients with haemophilia A and FVIII inhibitor
Smejkal, P.
Romanova, G.
Polak, P.
Penka, M.
HAEMOPHILIA, 2019, 25 : 157 - 157
[39] Efanesoctocog Alfa Versus Emicizumab in Adolescent and Adult Patients With Haemophilia A Without Inhibitors
Roman, Maria Teresa Alvarez
Kragh, Nana
Guyot, Patricia
Wilson, Amanda
Wojciechowski, Piotr
Margas, Wojciech
Wdowiak, Marlena
Santagostino, Elena
Arnaud, Alix
ADVANCES IN THERAPY, 2025, 42 (01) : 442 - 455
[40] Safety of recombinant activated factor VII for treatment of breakthrough bleeds in patients with congenital haemophilia A and inhibitors receiving emicizumab prophylaxis: Review of the real-world evidence
Kenet, Gili
Fujii, Teruhisa
HAEMOPHILIA, 2024, 30 (02) : 267 - 275

← 1 2 3 4 5 →